Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06672822

Intralesional Injection of STS in Treatment of Calcinosis (STSINJ)

An Open Label Evaluation of Intralesional Injection of Sodium Thiosulfate in the Treatment of Cutaneous or Tendon Calcinosis in Connective Tissue Disease

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Conditions Calcinosis Dermatomyositis Mixed Connective Tissue Disease (MCTD) Systemic Sclerosis (SSc)

Interventions Sodium Thiosulfate (STS)

Updated 3 times since 2024 Last updated: Sep 3, 2025 Started: Mar 17, 2025 Primary completion: Aug 31, 2028 Completion: May 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Calcinosis and Dermatomyositis and is currently actively recruiting participants. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2
Apr 2025 — Oct 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2024 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Robyn T. Domsic, MD, MPH

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States